Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has scheduled its fourth quarter and full year 2024 financial results release for March 3, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET the same day.
Investors can access the live call by dialing 800-715-9871 (US/Canada) or 1-646-307-1963 (International) with pass code 1983976. A webcast will be available through the investor relations section of Stereotaxis' website, and a phone replay will be accessible for one month after the call.
The company's technology has been utilized in treating over 150,000 patients globally across the United States, Europe, Asia, and other regions.
Stereotaxis (NYSE: STXS), un pioniere nella robotica chirurgica per interventi endovascolari minimamente invasivi, ha programmato la pubblicazione dei risultati finanziari del quarto trimestre e dell'anno intero 2024 per il 3 marzo 2025, prima dell'apertura dei mercati statunitensi. L'azienda ospiterà una conferenza telefonica e una trasmissione in webcast alle 8:30 a.m. ET lo stesso giorno.
Gli investitori possono partecipare alla chiamata dal vivo componendo il numero 800-715-9871 (US/Canada) o 1-646-307-1963 (Internazionale) con il codice di accesso 1983976. Un webcast sarà disponibile attraverso la sezione relazioni con gli investitori del sito web di Stereotaxis e una registrazione telefonica sarà accessibile per un mese dopo la chiamata.
La tecnologia dell'azienda è stata utilizzata nel trattamento di oltre 150.000 pazienti a livello globale, negli Stati Uniti, in Europa, in Asia e in altre regioni.
Stereotaxis (NYSE: STXS), un pionero en robótica quirúrgica para intervenciones endovasculares mínimamente invasivas, ha programado la publicación de sus resultados financieros del cuarto trimestre y del año completo 2024 para el 3 de marzo de 2025, antes de la apertura de los mercados en EE. UU. La compañía llevará a cabo una conferencia telefónica y transmisión por webcast a las 8:30 a.m. ET el mismo día.
Los inversores pueden acceder a la llamada en vivo marcando el 800-715-9871 (EE. UU./Canadá) o el 1-646-307-1963 (Internacional) con el código de acceso 1983976. Un webcast estará disponible a través de la sección de relaciones con inversionistas del sitio web de Stereotaxis, y una grabación telefónica estará accesible durante un mes después de la llamada.
La tecnología de la compañía ha sido utilizada en el tratamiento de más de 150,000 pacientes en todo el mundo, en los Estados Unidos, Europa, Asia y otras regiones.
스테레오택시스 (NYSE: STXS), 최소 침습 혈관 내 수술을 위한 로봇 수술의 선구자로, 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 3일에 예정하고 있습니다. 미국 시장 개장 전에 발표됩니다. 회사는 같은 날 오전 8:30 ET에 컨퍼런스 콜과 웹캐스트를 개최할 예정입니다.
투자자들은 800-715-9871 (미국/캐나다) 또는 1-646-307-1963 (국제)로 전화하여 패스코드 1983976으로 생방송에 참여할 수 있습니다. 스테레오택시스의 투자자 관계 섹션을 통해 웹캐스트가 제공되며, 전화 재생은 통화 후 한 달 동안 이용 가능합니다.
회사의 기술은 미국, 유럽, 아시아 및 기타 지역에서 전 세계적으로 150,000명 이상의 환자 치료에 사용되었습니다.
Stereotaxis (NYSE: STXS), un pionnier en robotique chirurgicale pour des interventions endovasculaires minimalement invasives, a prévu la publication de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 3 mars 2025, avant l'ouverture des marchés américains. La société tiendra une conférence téléphonique et un webcast le même jour à 8h30 ET.
Les investisseurs peuvent accéder à l'appel en direct en composant le 800-715-9871 (États-Unis/Canada) ou le 1-646-307-1963 (international) avec le code d'accès 1983976. Un webcast sera disponible dans la section des relations avec les investisseurs du site web de Stereotaxis, et un enregistrement téléphonique sera accessible pendant un mois après l'appel.
La technologie de l'entreprise a été utilisée dans le traitement de plus de 150 000 patients dans le monde entier, aux États-Unis, en Europe, en Asie et dans d'autres régions.
Stereotaxis (NYSE: STXS), ein Pionier in der chirurgischen Robotik für minimalinvasive endovaskuläre Eingriffe, hat die Veröffentlichung seiner finanziellen Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 auf den 3. März 2025 vor den Eröffnungen der US-Märkte angesetzt. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten.
Investoren können die Live-Konferenz telefonisch unter 800-715-9871 (USA/Kanada) oder 1-646-307-1963 (international) mit dem Zugangscode 1983976 erreichen. Ein Webcast wird über den Bereich Investorenbeziehungen auf der Website von Stereotaxis verfügbar sein, und eine Telefonwiedergabe wird einen Monat nach der Konferenz zugänglich sein.
Die Technologie des Unternehmens wurde zur Behandlung von über 150.000 Patienten weltweit in den USA, Europa, Asien und anderen Regionen eingesetzt.
- Technology has been used to treat over 150,000 patients globally
- None.
ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 fourth quarter and full year on Monday, March 3, 2025 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. ET that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis fourth quarter and full year 2024 financial results conference call |
| When: | Monday, March 3, 2025 at 8:30 a.m. ET (5:30 a.m. PT) |
| Dial In Number: | To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 1983976. |
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/. |
| Call Replay: | A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here. |
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.
Investor Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
When will Stereotaxis (STXS) release Q4 and full year 2024 earnings?
How can investors join the STXS Q4 2024 earnings call?
What time is the Stereotaxis (STXS) Q4 2024 earnings call?
How many patients have been treated with Stereotaxis (STXS) technology?
